A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Phase 3 Completed 210 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Timeline

Start: 2021-09-01
Primary completion: 2022-12-27
Completion: 2022-12-27

Outcome

Met primary endpoint

registry analysis (superiority test); 10 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -12.0 (95% CI -14.8 to -9.3); Mixed Models Analysis NCT05024032 ↗

registry analysis (superiority test); 15 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -17.5 (95% CI -20.3 to -14.8); Mixed Models Analysis NCT05024032 ↗

registry analysis (superiority test); 10 mg Tirzepatide vs Placebo; p <0.001; Odds Ratio (OR) 23.11 (95% CI 8.80 to 60.69); Regression, Logistic NCT05024032 ↗

registry analysis (superiority test); 15 mg Tirzepatide vs Placebo; p <0.001; Odds Ratio (OR) 26.53 (95% CI 9.61 to 73.24); Regression, Logistic NCT05024032 ↗

Publications

Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):551-560. doi: 10.1001/jama.2024.9217.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirzepatide	Peptide	10 mg	Subcutaneous
Subject	Tirzepatide	Peptide	15 mg	Subcutaneous